New drug combo shows promise against tough esophageal cancer
NCT ID NCT06143748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called cadonilimab, combined with chemotherapy and radiation, for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can better control the cancer and prevent it from coming back. About 46 participants will receive the treatment and be followed for three years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized radiation pulses could boost esophageal cancer treatment
- Can a condensed radiation blast plus chemo keep esophageal cancer at bay?
- New proton combo aims to improve esophageal cancer treatment
- New drug combo aims to stop Chemo-Induced nausea in cancer patients
- Remote exercise program aims to boost chemo completion in cancer patients
- New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers